Table III.
Predictors of Thiazide Nonpersistence
| Primary Analysis, FY 2004 (N=126,808) | Replication Analysis, FY 2006 (N=113,994) | ||
|---|---|---|---|
| Clinical Characteristic | Univariate Models OR (95% CI)a | Adjusted Model OR (95% CI)b | Adjusted Model OR (95% CI)b |
| Chlorthalidone | 1.60 (1.47–1.75) | 1.62 (1.48–1.76) | 1.49 (1.37–1.62) |
| Women | 1.05 (0.99–1.12) | 1.11 (1.04–1.18) | 1.15 (1.074–1.22) |
| Age | 1.009 (1.008–1.010) | 1.010 (1.009–1.011) | 1.014 (1.013–1.015) |
| AH failure in prior year | |||
| None | Reference | Reference | Reference |
| ≥1 | 1.04 (1.01–1.07) | 1.02 (0.98–1.05) | 1.04 (1.01–1.08) |
| ≥2 | 1.22 (1.14–1.29) | 1.19 (1.12–1.27) | 1.15 (1.08–1.22) |
| K‐sparing at index | 1.23 (1.19–1.28) | 1.19 (1.15–1.24) | 1.20 (1.14–1.25) |
| Concurrent AH started | 1.11 (1.07–1.15) | 1.05 (1.01–1.09) | 1.01 (0.97–1.04) |
| Ongoing AH drug therapy | |||
| None | 1.15 (1.12–1.19) | 1.17 (1.14–1.21) | 1.20 (1.16–1.24) |
| 1 or 2 | Reference | Reference | Reference |
| ≥3 | 1.13 (1.08–1.18) | 1.10 (1.06–1.15) | 1.07 (1.02–1.11) |
| Initial thiazide dose | |||
| Micro (≤12.5 mg) | 0.95 (0.93–0.97) | 0.95 (0.93–0.97) | 0.96 (0.94–0.99) |
| Low (12.5 mg<dose ≤25 mg) | Reference | Reference | Reference |
| High (>25 mg) | 1.19 (1.120–1.27) | 1.19 (1.11–1.26) | 1.07 (1.00–1.16) |
Abbreviations: AH, antihypertensive drug; FY, fiscal year; K‐sparing, potassium‐sparing diuretic (eg, spironolactone, amiloride, triamterene). aOdds ratios (ORs) and 95% confidence intervals (CIs) for univariate models separately examining the association between nonpersistence and each individual clinical characteristic. bORs and 95% CIs for a single multivariable logistic regression model controlling for all clinical characteristics specified in the Table.